Outlook: A tough job at British Biotech
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.IF THERE were a list of the world's worst jobs, then running British Biotech would rank right up there alongside Japanese finance minister and public apologist for Camelot. Yesterday the 69-year old chairman of British Biotech, John Raisman, announced he was making way for the youthful figure of Christopher Hampson, aged 66.
None of Mr Hampson's previous incarnations - ICI, Yorkshire Electricity, Costain - could possibly prepare him for this job and he freely admits that he took a long, hard, sceptical look before accepting it.
Now that he is on board, however, he is looking forward to maintaining the group's tradition of innovative research and development and successfully commercialising its products. If half of the claims made by its ex-director of clinical trials, Andrew Millar, are true, then British Bio's approach to research is certainly innovative.
As for successfully commercialising its products, Zacutex is dead in the water while the future of the cancer treatment Marimastat is hanging by a thread. Repeating all the trials for Zacutex that Dr Millar unblinded would be prohibitively expensive. British Bio can only hope that Marimastat does not face the same prospect.
What else can Mr Hampson look forward to? Well, there is the chance to appear before a Commons select committee (hankie at the ready). Then, of course, there is the task of liaising with all those supportive shareholders like Perpetual.
The fact that Mr Hampson will be paid circa pounds 80,000 to do the job suggests that he will need to be a little more than the traditional non-executive, part-time figure head. Of course, his most urgent task will be to fill the least appealing job of all - the one of chief executive which Keith McCullagh is vacating in September. Mr Hampson says British Bio will look internally and externally. Like the Japanese political institution, it will probably have to fall back on one of its own.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments